The in vivo resemblance of our novel 3DD cell culture model can be applied to optimize the dosing regimens of anti-cancer therapies to overcome HER2 resistance, thus enhancing the clinical translation of the efficacious combination drugs. This evidence concerns the gene ERBB2 and cancer.